Small molecule · developed by Scynexis
SCY-635 is an oral tablet studied in hepatitis C infection, given at 300 mg twice daily for 28 days in a trial.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01265511 | Phase 2 | Hepatitis C Infection | Completed | SCYX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hepatitis C Infection
Updated Nov 1, 2026. Something wrong or missing? Report it on the SCYX page.
See SCYX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SCYX catalysts and pipeline →